Description

ML218-d9 is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier[1].–Applications–Formula-C19H17D9Cl2N2O-Citation–References-[1]Xiang Z, et al. The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson’s Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. -CASNumber–MolecularWeight-378.38-Compound Purity–SMILES-O=C(C1=CC(Cl)=CC(Cl)=C1)NC[C@H]2[C@@]3([H])[C@]2([H])CN(C3)CCC(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H]-Research_Area-Neurological Disease-Solubility-10 mM in DMSO-Target-Calcium Channel-Isoform–Pathway-Membrane Transporter/Ion Channel;Neuronal Signaling-MCE Product type-Isotope-Labeled Compounds